Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Expected to Post Earnings of -$0.57 Per Share

Equities research analysts expect that Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) will report earnings per share of ($0.57) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Crinetics Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.62) and the highest estimate coming in at ($0.51). Crinetics […]

Related Keywords

Stephenf Betz , ,Charles Schwab Investment Management Inc ,Zacks Investment Research ,Crinetics Pharmaceuticals Get Rating ,Nuveen Asset Management ,Crinetics Pharmaceuticals Inc ,Nasdaq ,Crinetics Pharmaceuticals ,Get Rating ,Zacks Investment ,Crinetics Pharmaceutical ,Investment Research ,Asset Management ,Street Corp ,Schwab Investment Management ,Nasdaq Crnx ,Crnx ,Medical ,Ratings ,Consensus ,